Every 424B that LB Pharmaceuticals Inc (LBRX) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 424B covers the supplement that carries the terms of a priced offering, so if you follow LBRX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LBRX filings page.
LB Pharmaceuticals Inc (LBRX) filed a prospectus supplement to its Form S-1, updating the prospectus to include a current report on the appointment of Joseph M. Miller as Chief Financial Officer effective September 2, 2026. The filing outlines his compensation terms and an inducement stock option grant.
Mr. Miller’s employment agreement provides a fixed base salary, target bonus opportunity, equity incentives outside the company’s 2025 Equity Incentive Plan under Nasdaq Listing Rule 5635(c)(4), and defined severance and COBRA benefits upon certain terminations, including enhanced protection in connection with a change of control.
LB Pharmaceuticals Inc. filed a prospectus supplement to its Form S-1 resale registration, updating investors with its June 30, 2026 quarterly report. The registration relates to securities issued in a February 2026 private placement of 3,306,571 common shares and pre-funded warrants exercisable for up to 1,417,107 additional shares. As of June 30, 2026, the company held $327.8 million in cash, cash equivalents and marketable securities and reported total assets of $361.7 million. It recorded a six‑month net loss of $70.7 million, driven by $58.8 million in research and development spending and $17.2 million in general and administrative expenses as it advances its lead neuromedicine candidate LB‑102 through a Phase 3 schizophrenia trial and Phase 2 bipolar depression program. A subsequent July 2026 private placement raised an additional $150.0 million in gross proceeds.
LB Pharmaceuticals Inc. entered into a private placement with institutional investors to sell 3,577,560 shares of common stock and pre-funded warrants to purchase up to 715,513 shares. Shares are priced at $34.94 and the pre-funded warrants at $34.9399 with a de minimis exercise price of $0.0001 per share. The company expects approximately $150.0 million in gross proceeds, before expenses.
The pre-funded warrants are immediately exercisable, do not expire, and include beneficial ownership limits of 4.99% or 9.99%, adjustable up to 19.99% with notice. LB Pharmaceuticals plans to use the proceeds, together with existing cash, to expand development of LB-102 into additional indications, potentially including negative symptoms of schizophrenia and Alzheimer’s disease agitation/psychosis, and for working capital and general corporate purposes. A Registration Rights Agreement requires filing an S-3 resale registration for the shares and warrant shares within 90 days of closing and using reasonable best efforts to obtain effectiveness within 90 days of filing.
LB Pharmaceuticals Inc. filed a prospectus supplement to its Form S-1, updating the existing prospectus by incorporating information from a new Current Report on Form 8-K. The update centers on a press release announcing accelerated timing of topline results from the Phase 3 NOVA-2 clinical trial of LB-102 in schizophrenia. The press release, dated July 22, 2026, is incorporated by reference except for its quoted statements. The company’s common stock trades on The Nasdaq Global Market under the symbol LBRX, and the last reported sale price was $32.31 per share on July 21, 2026.
LB Pharmaceuticals Inc filed a prospectus supplement dated June 10, 2026 that incorporates a Form 8-K reporting the resignation of Chief Medical Officer Anna Eramo, M.D., effective June 15, 2026, and her transition to an adviser and consultant through September 15, 2026. The supplement describes a Separation and Consulting Agreement providing consulting services during a three-month Consulting Period, continuation of option vesting per company plans, reimbursement of COBRA healthcare premiums for up to 12 months, payment of base salary on a monthly basis through June 15, 2027, a prorated 100% target annual bonus for 2026, and acceleration such that 66,143 unvested option shares will vest and become exercisable on September 15, 2026. The company states Dr. Eramo’s departure is for personal reasons, is not related to clinical program operations or practices, and is not expected to have a material impact on clinical development activities or disclosed clinical milestones. The prospectus supplement updates the Registration Statement on Form S-1 (Registration No. 333-294900) and should be read with the Prospectus.
LB Pharmaceuticals Inc filed a prospectus supplement to its Registration Statement on Form S-1 to update the Prospectus with information from a Current Report on June 9, 2026.
The company held its 2026 Annual Meeting on June 3, 2026. Stockholders elected three Class I directors for three-year terms: Robert A. Lenz, M.D., Ph.D. (20,059,577 votes for), Rebecca Luse (18,530,680 votes for), and Ran Nussbaum (18,748,511 votes for). Stockholders also ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm with 23,275,974 votes for.
LB Pharmaceuticals Inc filed a prospectus supplement to its Form S-1 to update the registration materials with information from its Form 10-Q for the quarterly period ended March 31, 2026.
The supplement incorporates the company’s March quarter results: combined cash, cash equivalents and marketable securities of $365.6 million, a net loss of $(19.054) million for the three months ended March 31, 2026, and 28,676,652 shares of common stock outstanding as of May 7, 2026. The filing discloses a February 2026 private placement that raised approximately $100.0 million (net proceeds ~$93.8 million) and reiterates that current capital resources are expected to fund operations into at least the second quarter of 2029.
LB Pharmaceuticals Inc registered for resale up to 4,778,491 shares of Common Stock pursuant to a prospectus dated April 14, 2026, covering (i) 4,723,678 shares related to a February 4, 2026 PIPE (including 3,306,571 outstanding shares and 1,417,107 issuable upon exercise of pre-funded warrants) and (ii) 54,813 shares issued to Maxim upon exercise of prior warrants. The registration permits resale "from time to time" by the Selling Stockholders; the company will not receive proceeds from these resales except for the $0.0001 per-share exercise price of any pre-funded warrants exercised for cash. The prospectus states resale methods may include fixed price, market-price, negotiated transactions, underwriters, broker-dealers or agents. The company reported a Nasdaq last sale price of $25.69 per share as of April 2, 2026.